Helena Buso MD , Davide Firinu MD , Renato Finco Gambier MD , Riccardo Scarpa MD, PhD , Giulia Garzi MD , Valentina Soccodato MD , Giulia Costanzo MD , Andrea G. Ledda MD , Nicolò Rashidy MD , Ilaria Bertozzi MD , Stefania Nicola MD , Giulio Tessarin MD , Mauro Ramigni MD , Cinzia Piovesan MSc , Fabrizio Vianello MD , Andrea Vianello MD , Stefano Del Giacco MD , Vassilios Lougaris MD , Luisa Brussino MD , Mark G. Jones MD, PhD , Francesco Cinetto MD, PhD
{"title":"Lung function trajectories in common variable immunodeficiencies: An observational retrospective multicenter study","authors":"Helena Buso MD , Davide Firinu MD , Renato Finco Gambier MD , Riccardo Scarpa MD, PhD , Giulia Garzi MD , Valentina Soccodato MD , Giulia Costanzo MD , Andrea G. Ledda MD , Nicolò Rashidy MD , Ilaria Bertozzi MD , Stefania Nicola MD , Giulio Tessarin MD , Mauro Ramigni MD , Cinzia Piovesan MSc , Fabrizio Vianello MD , Andrea Vianello MD , Stefano Del Giacco MD , Vassilios Lougaris MD , Luisa Brussino MD , Mark G. Jones MD, PhD , Francesco Cinetto MD, PhD","doi":"10.1016/j.jaci.2024.10.037","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Respiratory disease is a frequent cause of morbidity and mortality in common variable immunodeficiencies (CVIDs); however, lung function trajectories are poorly understood.</div></div><div><h3>Objective</h3><div>We sought to determine lung physiology measurements in CVIDs, their temporal trajectory, and their association with clinical and immunologic parameters.</div></div><div><h3>Methods</h3><div>This retrospective study from 5 Italian centers included patients with CVIDs who had longitudinal pulmonary function tests (PFTs) and chest computed tomography scan available. Applying the European Respiratory Society/American Thoracic Society 2021 standard, PFTs were expressed as percentile value within the normal distribution of healthy individuals, with the 5th percentile identified as lower limit of normal (LLN). The association of lung function with clinical and immunologic parameters was investigated.</div></div><div><h3>Results</h3><div>The study included 185 patients with CVIDs; 64% had at least 1 lung comorbidity (bronchiectasis: 41%; granulomatous interstitial lung diseases: 24%). At first spirometry, median FEV<sub>1</sub> was 3.07 L (interquartile range: 2.40-3.80 L), at the 32nd percentile (6th-61st percentile), and median forced vital capacity (FVC) was 3.70 L (interquartile range: 3.00-.54 L), at the 29th percentile (7th-49th percentile). Of patients, 23% had FEV<sub>1</sub> < LLN, and 21% had FVC < LLN. Switched-memory B cells <2% were associated with both FEV<sub>1</sub> < LLN (odds ratio 7.58) and FVC < LLN (odds ratio 3.55). In 112 patients with at least 5 years of PFTs, we found no significant difference between measured and predicted annual decline of FEV<sub>1</sub> (25.6 mL/year vs 20.7 mL/year) and FVC (15.6 mL/year vs 16.2 mL/year).</div></div><div><h3>Conclusions</h3><div>In our study, lung volumes of the majority of patients with CVIDs were in the lower third of normal distribution of healthy individuals. After diagnosis, rate of lung decline was not accelerated.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"155 3","pages":"Pages 1027-1035"},"PeriodicalIF":11.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674924012302","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Respiratory disease is a frequent cause of morbidity and mortality in common variable immunodeficiencies (CVIDs); however, lung function trajectories are poorly understood.
Objective
We sought to determine lung physiology measurements in CVIDs, their temporal trajectory, and their association with clinical and immunologic parameters.
Methods
This retrospective study from 5 Italian centers included patients with CVIDs who had longitudinal pulmonary function tests (PFTs) and chest computed tomography scan available. Applying the European Respiratory Society/American Thoracic Society 2021 standard, PFTs were expressed as percentile value within the normal distribution of healthy individuals, with the 5th percentile identified as lower limit of normal (LLN). The association of lung function with clinical and immunologic parameters was investigated.
Results
The study included 185 patients with CVIDs; 64% had at least 1 lung comorbidity (bronchiectasis: 41%; granulomatous interstitial lung diseases: 24%). At first spirometry, median FEV1 was 3.07 L (interquartile range: 2.40-3.80 L), at the 32nd percentile (6th-61st percentile), and median forced vital capacity (FVC) was 3.70 L (interquartile range: 3.00-.54 L), at the 29th percentile (7th-49th percentile). Of patients, 23% had FEV1 < LLN, and 21% had FVC < LLN. Switched-memory B cells <2% were associated with both FEV1 < LLN (odds ratio 7.58) and FVC < LLN (odds ratio 3.55). In 112 patients with at least 5 years of PFTs, we found no significant difference between measured and predicted annual decline of FEV1 (25.6 mL/year vs 20.7 mL/year) and FVC (15.6 mL/year vs 16.2 mL/year).
Conclusions
In our study, lung volumes of the majority of patients with CVIDs were in the lower third of normal distribution of healthy individuals. After diagnosis, rate of lung decline was not accelerated.
期刊介绍:
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.